Abstract
Clinical Treatment Score at 5 years (CTS5) is a prognostic tool to estimate distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women with oestrogen receptor-positive (ER-positive) breast cancer. The validity of CTS5 was tested in a retrospective cohort of patients diagnosed with early ER-positive breast cancer. The primary endpoint was DR in years 5-10. The primary analysis cohort consisted of postmenopausal women, with premenopausal women as a secondary analysis cohort. Cox regression models were used to determine the prognostic value of CTS5 and Kaplan-Meier curves were used with associated 10-year DR risks (%). 2428 women were included with a median follow-up of 13.4 years. The CTS5 was significantly prognostic in both postmenopausal (N = 1662, HR = 2.18 95% CI (1.78-2.67)) and premenopausal women (N = 766, HR = 1.84 95% CI (1.32-2.56)). The 10-year DR risks were 2.9% (1.9-4.5), 7.2% (5.3-9.9), and 12.9% (10.0-16.7) for low, intermediate and high risk in postmenopausal women and 3.8% (2.2-6.7), 6.9% (4.4-10.8), and 11.1% (7.4-16.5) in premenopausal women, respectively. The number of observed DRs was significantly greater than expected in those predicted to be at high risk by CTS5 but this disc...Continue Reading
References
Sep 8, 2005·Journal of the National Cancer Institute·Paul E GossJoseph L Pater
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanAlison Jones
Dec 12, 2012·Lancet·Christina DaviesRichard Peto
Sep 17, 2013·The Lancet Oncology·Dennis C SgroiMitch Dowsett
Feb 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin FilipitsUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ivana SestakMichael Gnant
Apr 19, 2015·Breast Cancer Research : BCR·Kathrin Strasser-WeipplPaul E Goss
Jun 7, 2016·The New England Journal of Medicine·Paul E GossWendy R Parulekar
Jul 13, 2016·Journal of the National Cancer Institute·Richard BuusMitch Dowsett
Feb 22, 2017·Lancet·David CameronUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Sep 20, 2017·Journal of the National Cancer Institute·Erik J BlokUNKNOWN IDEAL Study Group
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Nov 22, 2017·The Lancet Oncology·Marco ColleoniUNKNOWN SOLE Investigators
Apr 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettJack Cuzick
Dec 5, 2018·The Lancet Oncology·Eleftherios P MamounasNorman Wolmark